108 related articles for article (PubMed ID: 21714992)
1. Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
Orr JM; Barnett JC; Leath CA
Gynecol Oncol; 2011 Sep; 122(3):501-4. PubMed ID: 21714992
[TBL] [Abstract][Full Text] [Related]
2. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
[TBL] [Abstract][Full Text] [Related]
3. Risk of invasive cervical cancer after three consecutive negative Pap smears.
Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
J Med Screen; 2003; 10(4):196-200. PubMed ID: 14738657
[TBL] [Abstract][Full Text] [Related]
4. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
5. Cervical cytology associated with levonorgestrel contraception.
Misra JS; Engineer AD; Tandon P
Acta Cytol; 1995; 39(1):45-9. PubMed ID: 7847008
[TBL] [Abstract][Full Text] [Related]
6. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.
Zola P; Fuso L; Mazzola S; Piovano E; Perotto S; Gadducci A; Galletto L; Landoni F; Maggino T; Raspagliesi F; Sartori E; Scambia G
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S150-4. PubMed ID: 17868785
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
8. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
9. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening.
Kennedy AW; Salmieri SS; Wirth SL; Biscotti CV; Tuason LJ; Travarca MJ
Gynecol Oncol; 1996 Oct; 63(1):14-8. PubMed ID: 8898161
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
Costa S; Negri G; Sideri M; Santini D; Martinelli G; Venturoli S; Pelusi C; Syrjanen S; Syrjanen K; Pelusi G
Gynecol Oncol; 2007 Jul; 106(1):170-6. PubMed ID: 17481701
[TBL] [Abstract][Full Text] [Related]
11. [Are analyses of cytological cervix smears from young women more harmful than beneficial?].
Skjeldestad FE; Hagen B; Hagmar B; Iversen OE; Juvkam KH; Steen R; Thoresen S; Hareide B
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1782-5. PubMed ID: 17599128
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
13. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of cervical cancer in women age sixty and over.
Fox KV; Shah CA; Swisher EM; Garcia RL; Mandel LS; Gray HJ; Swensen RE; Goff BA
Gynecol Oncol; 2008 Apr; 109(1):53-8. PubMed ID: 18255127
[TBL] [Abstract][Full Text] [Related]
15. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.
Wallin KL; Wiklund F; Angström T; Bergman F; Stendahl U; Wadell G; Hallmans G; Dillner J
N Engl J Med; 1999 Nov; 341(22):1633-8. PubMed ID: 10572150
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer screening in a rural population of Zimbabwe.
Thistle PJ; Chirenje ZM
Cent Afr J Med; 1997 Sep; 43(9):246-51. PubMed ID: 9509642
[TBL] [Abstract][Full Text] [Related]
18. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives.
Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
J Med Screen; 2005; 12(1):7-11. PubMed ID: 15814014
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer complicated by pregnancy: episiotomy site recurrences following vaginal delivery.
Cliby WA; Dodson MK; Podratz KC
Obstet Gynecol; 1994 Aug; 84(2):179-82. PubMed ID: 8041526
[TBL] [Abstract][Full Text] [Related]
20. Cervicography: adjunctive cervical cancer screening by primary care clinicians.
Ferris DG; Payne P; Frisch LE; Milner FH; diPaola FM; Petry LJ
J Fam Pract; 1993 Aug; 37(2):158-64. PubMed ID: 8336097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
